Julio Montaner

Last updated
Julio S.G. Montaner

OC
Born (1956-04-13) April 13, 1956 (age 67) [1]
Buenos Aires, Argentina
NationalityArgentine-Canadian
Alma mater University of Buenos Aires
Known forHAART, STOP HIV-AIDS, TasP
SpouseDorothée
ChildrenMichaela, Camila, Fernando and Gabriela
Awards Albert Einstein World Award of Science (2010)
Queen Elizabeth II Diamond Jubilee Medal
Scientific career
Fields HIV/AIDS
InstitutionsBritish Columbia Centre for Excellence in HIV/AIDS

Julio S. G. Montaner, OC, OBC FRCPC, FCCP, FACP, FRSC (born April 13, 1956) is an Argentine-Canadian physician, professor and researcher. [2] [3] He is the director of the British Columbia Centre for Excellence in HIV/AIDS, the chair in AIDS Research and head of the Division of AIDS in the Faculty of Medicine at the University of British Columbia and the past-president of the International AIDS Society. [2] He is also the director of the John Ruedy Immunodeficiency Clinic, and the Physician Program Director for HIV/AIDS PHC. [2] He is known for his work on HAART (Highly Active Antiretroviral Therapy), a role in the discovery of triple therapy as an effective treatment for HIV in the late 1990s, and a role in advocating the "Treatment as Prevention" Strategy in the mid-2000s, led by Myron Cohen of the HPTN 052 trial. [2]

Contents

Early life and career

Montaner was born in Buenos Aires, Argentina in 1956, the son of Julio Gonzalez Montaner, a pulmonary specialist. [4] His father initially doubted that Montaner would follow in his footsteps, but after entering medical school, he developed a passion for medicine. [4] He received an M.D. with Honours from the University of Buenos Aires in Argentina in 1979. [2]

Montaner originally planned on following his father's career in pulmonary medicine, and accepted an invitation to do a one-year post-doctoral fellowship at the University of British Columbia in 1981 in the Pulmonary Research Laboratory, which was directed at the time by James C. Hogg. [5] His initial research focused on animal models of acute lung injury. [6] Montaner initially planned on returning to Argentina after completing his fellowship. [5] After meeting his future wife at St. Paul's Hospital in the early 1980s, he decided to remain in Canada. [5] He completed his residency at the University of British Columbia in the Department of Internal Medicine and Respiratory Medicine and was appointed Chief Resident for the Department of Medicine from 1986 to 1987. [2]

Montaner then joined the faculty at St. Paul's Hospital/University of British Columbia in Vancouver, British Columbia, in 1987. [2] John Ruedy, at the time the head of the Department of Medicine at St. Paul's Hospital, invited him to run the new HIV department that was being established in response to the emerging AIDS crisis. [5] Ruedy appointed him as the director of the AIDS Research Program and the Infectious Disease Clinic in 1989. [6] Montaner's shift to HIV research began when he encountered AIDS patients with Pneumocystis carinii pneumonia while completing his training in pulmonary medicine. [5] He encountered the opportunity to test AZT monotherapy for HIV as part of his work on PCP, which sparked an interest in HIV research. [5]

Montaner was the only member of the HIV department at St. Paul's Hospital when it was first founded. [6] He became the founding co-director of the Canadian HIV Trials Network in 1990 with Martin Schechter. In 1992, he was joined by Michael O’Shaughnessy to found the B.C. Centre for Excellence in HIV/AIDS in 1992. [6]

Montaner was appointed a National Health Research Scholar of Canada (NHRDP) from 1988 to 1998. [2] In 1996, Montaner presented the results of his pioneering research on triple therapy to treat HIV infections at the XI International AIDS Conference in Vancouver, creating new standard for HIV drug therapy. [6] In 1997, he was appointed a Professor of Medicine at the University of British Columbia. [2]

Montaner served as the president of the International AIDS Society from 2008 to 2010, and as of 2013, continues to serve as an elected member of the Council of the International AIDS Society after his term as president ended. [2] As of 2013, he also serves as the director of clinical activities at the BC Centre of Excellence in HIV/AIDS, a professor of medicine at UBC, physician program director for HIV/AIDS PHC and continues to serve as the director of the John Ruedy Immunodeficiency Clinic at St. Paul's Hospital. [2]

Montaner is the editor of the B.C. Centre Therapeutic Guidelines and oversees its Drug Distribution Program. [2] In 2002, he was awarded the $1 million Distinguished Researcher Award in HIV.1 He was awarded the Avant-Garde Award of $2.5 million over 5 years, from the National Institute on Drug Abuse of the National Institutes of Health, in support of the "Seek and Treat for Optimal Outcomes and Prevention in HIV & AIDS in IDU (STOP HIV/AIDS)" strategy of treatment as prevention in 2010. [7]

Research

Respiratory medicine research

As a post-doctoral fellow and resident, Montaner's research was initially focused on respiratory medicine. [5] He participated in and led a series of studies on the role of adjunctive corticosteroids in treating Pneumocystis carinii pneumonia (PCP) patients. [5] PCP is an opportunistic infection commonly found in AIDS-stage HIV positive patients and was one of the major killers of HIV-positive patients at that time. [8] [9] Montaner and his colleagues found that oral corticosteroid treatment administered early to AIDS patients experiencing their first moderate to severe P. carinii pneumonia episode prevented early deterioration and improved oxygen saturation, a key indicator of survival in PCP patients. [10] Montaner and the study's co-authors found that only 5.6% of the patients given Prednisone (a corticosteroid) reached the study-end point of a 10% decrease in oxygen saturation compared to 42.1% of the patients on the placebo drug. [10] The Prednisone group also demonstrated increased long-term exercise tolerance, another indicator of long-term survival. [9]

As a result of this study, Montaner was one of the first doctors to implement the strategy of treating PCP patients with steroids. [5] The approach of treating immunosuppressed patients with steroids, which are anti-inflammatory drugs, was unorthodox at the time but Montaner pursued this strategy as he "believed [HIV] was a matter of immune dysregulation as much as suppression.". [5] Montaner and his colleagues published their findings in Chest in 1989 and the Annals of Internal Medicine in 1990. [9] [10] Montaner's research and similar findings from other pulmonary researchers at the time led to the release of a consensus statement from a NIH-University of California Expert Panel recommending the treatment of HIV-positive PCP patients with corticosteroids. [8]

HIV/AIDS research

Montaner has authored over 450 publications on HIV/AIDS dating back to the late 1980s. [2] After he was appointed the director of the AIDS Research Program and the Immunodeficiency Clinic at St. Paul's Hospital; Montaner focused his research on antiretroviral therapy and HIV treatment regimes. [5]

Triple therapy (HAART)

His research in the mid-1990s contributed to the development and implementation of anti-HIV triple-drug therapy (HAART). [5] [11] At the XI International AIDS Society-USA (IAS-USA) Conference in 1996, Montaner presented the findings of the INCAS group, which consisted of HIV-positive cohorts in Italy, Netherlands, Canada, Australia and the United States. [11] The INCAS group's initial findings were that treating HIV-1 positive adults with a combination of three drugs (nevirapine, didanosine and zidovudine) resulted in a greater decrease in viral load than a combination of two drugs. [11] He also announced an association between decreased viral load and improved outcomes, as well as decreased mortality. The study also reported a decrease in viral load of less than 20 HIV RNA copies per mL of blood in some patients in the triple therapy group. [11] The study was conducted as a 52-week double-blind study on 151 antiretroviral-naïve HIV-positive patients that had never had a record of an AIDS-defining condition. [11] This discovery was adopted as part of the antiretroviral treatment guidelines by the IAS and is the basis of the modern-day HAART treatment regimen. [12] Montaner said about the discovery: "The sense of excitement was absolutely palpable. It was incredible. Within months, mortality, death rates and progression to AIDS among people taking triple therapy was down to nothing. This happened in Vancouver." [6]

In 1998, the results of the INCAS randomized double-blind clinical trial examining a combination of Nevirapine, Didanosine and Zidovudine as treatment for HIV-positive patients was published in the Journal of the American Medical Association . This paper reported the data initially presented by Montaner and his colleagues at the XI IAS Conference. [13] The paper demonstrated their findings of a greater decrease in plasma HIV-1 RNA (an indicator of HIV viral load) in patients treated with the combination of the three drugs as opposed to patients treated with a regimen of only two of the drugs, which was the standard of care in the mid 1990s. [12] [13] The percentage of patients in the triple drug therapy group with a viral load below 20 copies per mL after 52 weeks of treatment was 52%, compared to 12% for patients in the zidovudine plus didanosine group and 0% for the zidovudine plus nevirapine group (P < 0.01). [13] The trial demonstrated that a triple therapy regimen of nevirapine, didanosine and zidovudine given as a combination reduces viral load among HIV-1 positive adults significantly more than a combination of two of the drugs. [13]

Drug resistance

Montaner and his colleagues at the BC-CfE have conducted research on the development of drug resistance to triple-drug therapy cocktails. [2] [5] In 2005, Montaner and his colleagues published a study in The Journal of Infectious Diseases characterizing the development of antiretroviral resistance among a cohort of 1191 initially antiretroviral-naïve HIV positive British Columbians. [14] The results indicated that a high baseline plasma viral load, poor adherence and the inclusion of non-nucleoside reverse-transcriptase inhibitors (NNRTIs) in the initial drug cocktail were all predictors of development of antiretroviral resistance. [14] Montaner was coauthor on Robert Hogg's paper demonstrating that resistance to NNRTIs resulted in greater mortality than the development of resistance to protease inhibitors. [15] Montaner and the BC-CfE continue to focus research efforts on multi-drug resistance and its predictors. [2] [3] [5]

Treatment as prevention strategy (TasP)

Montaner was also central in the creation and implementation of the Treatment as Prevention strategy (TasP). [2] [5] The Treatment as Prevention strategy is based on the premise that administering HAART to all medically eligible HIV positive individuals will decrease transmission rates. [16] In 2006, Montaner, Robert Hogg, and colleagues at the B.C. Centre for Excellence in HIV/AIDS published an article in The Lancet promoting early and global access to HAART treatment as a strategy not just to decrease mortality and progression to AIDS, but also as a method of reducing HIV transmission. [17] HAART treatment has been found to reduce viral load to undetectable levels in the female genital tract, semen and blood. [17] Montaner et al. suggested that this would therefore decrease transmission risk, based on studies of significant decreases in mother-to-child transmission with the use of HAART. [17] Montaner and his colleagues presented evidence from multiple clinical trials and cohort studies showing reduction in HIV transmission among sero-discordant couples with the use of HAART, as well as regional negative correlations between increased HAART access and use and HIV transmission rates. [17]

Based on data from Taiwan and British Columbia, Montaner and his colleagues posited that approximately a 50% reduction in HIV transmission could be attributed to widespread HAART adherence. [17] [18] This suggested that Treatment as Prevention was a cost-effective strategy, based on an estimated lifetime treatment cost of $241 000 in 2001 in the United States for a new HIV infection. [17] [19] Montaner and his colleagues created a hypothetical population-based model that demonstrated that with worldwide access to HAART, the short-term cost would be much less compared to the long-term cost of treating new infections as a result of the decrease in transmission rate. [17] Their population-based model demonstrated, in an optimistic prediction, that HIV global prevalence could be reduced by a factor of 70 over 45 years. [17] Montaner's research also addressed concerns of HIV drug resistance evolving from increased and early access to HAART by citing evidence from studies supporting the idea that fears of drug resistance should not prevent widespread HAART distribution. [17] [20] In a 2011 article published in Lancet, Montaner stated that "The evidence is in: treatment is prevention. Treatment dramatically prevents morbidity and mortality, HIV transmission, and tuberculosis. Furthermore, treatment prevents HIV transmission in vertical, sexual, and injection drug use settings; indeed, a very welcome double hat-trick. The challenge remains to optimise the impact of this valuable intervention. Failure to do so is not an option." [21] Montaner cited the findings of the landmark study HPTN 052, that HAART use can reduce HIV transmission by 96% in sero-discordant heterosexual couples, as compelling evidence for implementing the "Treatment as Prevention" Strategy. [22] These findings supported the BC-CfE's finding of a negative correlation between an increased number of HIV positive individuals on HAART and new cases of HIV. [23] These results were from a population-based study in B.C. that aimed to estimate the correlation between new HIV infections, HAART coverage and HIV-1 plasma viral load published in Lancet in 2010. [22] [23] The 2010 Lancet study demonstrated a population-level association between increased HAART coverage and decreased viral load and new HIV infections, which supported the idea of decreased HIV transmission as a secondary benefit of expanding HAART coverage. [23]

Currently, in British Columbia, Montaner has a role in the largely defunct Seek and Treat for Optimal Prevention of HIV/AIDS (STOP HIV/AIDS) program with assistance from a paltry $2.5 million grant from the US National Institute of Drug Abuse of the NIH. [24] This program is based on Cohen's HPTN 052 research supporting Treatment as Prevention and aims to expand access to HAART among hard-to-reach and vulnerable populations in the Downtown East-Side area of Vancouver. [24] The goal of the program is to decrease HIV/AIDS-related mortality in British Columbia and evaluate any corresponding decrease in new HIV cases in B.C. [24] In data published in 2010, Montaner and the BC-CfE reported a reduction of approximately 65% in new HIV cases in B.C. [23]

Safe injection sites and harm reduction

Montaner is a proponent of harm reduction policy and played a minor role for his colleagues at the BC-CfE, was involved in founding and supporting the Insite Safe Injection facility in Vancouver's Downtown East-Side. [25] Montaner has co-authored many studies on the effect of safe injection facilities on drug overdoses and deaths, HIV and Hepatitis C infections and the spread of other blood-borne pathogens. [25] [26] [27] The research of Montaner and his colleagues was instrumental in the Supreme Court of Canada's 2011 ruling in Canada (AG) v PHS Community Services Society , which allowed Insite's exemption status to continue. [26] [27] [28]

Current research interests

Montaner's current major research interests are harm reduction (including safe injection sites and needle exchange programs), treating hard-to-reach HIV-positive populations, and developing new antiretrovirals. [2] [3] [7] He is being sued by former colleagues for blocking access to data mutually collected. He is also focusing on optimizing HAART treatment and authoring further studies on the "Treatment as Prevention" strategy. Since the last 2000s, he has shifted the focus of the BC-CfE to focus on HAART toxicity, multi-drug resistance and antiretroviral adherence. [2] [5] He received a grant of $2.5 million over 5 years in 2008 from the National Institute on Drug Abuse to support his "Seek and Treat for Optimal Outcomes and Prevention in HIV & AIDS in IDU (STOP HIV/AIDS)" project. [7] He also is working on improving the engagement and treatment of hard-to-reach or rural HIV positive populations as part of a $48 million grant from the Ministry of Health of the Province of British Columbia. [7]

Controversy

Early career controversy and HIV/AIDS stigma

Early in his career, Montaner and his colleagues faced extensive stigma during the early days shortly after the B.C. Centre for Excellence and the Canadian HIV Trials Network were founded. [5] There were many attempts to divert funding from HIV research at the time and he encountered significant resistance from the provincial government of British Columbia due to the stigma surrounding HIV. [6] Montaner started his career at a time where very little was known about HIV and how it was spread, and there was much resistance from some of the staff and medical community at St. Paul's Hospital about their developing reputation as a center for HIV/AIDS in the early 1990s. [4] [6]

The Tiko Kerr Case

In 2005, Montaner was central in the battle to obtain experimental drugs to treat Vancouver artist and activist Tiko Kerr. [29] Kerr was diagnosed with HIV in the 1980s and over time, had developed resistance to every HIV drug on the market due to being treated with single-drug therapy in the early 1990s before the discovery of triple-drug therapy. [29] [30] Montaner pressured Health Canada to allow Kerr and five other patients with drug-resistant HIV to receive two experimental HIV drugs, TMC114 and TMC125.28 [31] The drugs had not yet been released to market in Canada due to concerns about drug toxicity. [29] Montaner argued for access to the drugs under ground of compassionate use. Health Canada initially denied the appeal, but after public pressure from Montaner and other HIV activists, granted permission for the use of the drugs in a clinical trial. [29] Kerr and 3 others were started on the two drugs, as two of the men originally in need of the drugs had died by the time permission was granted by Health Canada. [29] Kerr credits Montaner with saving his life due to his efforts in obtaining the drugs. [31] In 2009, 4 years after starting the clinical trial, Kerr's CD4+ count has significantly improved and his viral load has fallen, and he appears in general good health, indicating that the drugs are working. [32]

Controversy surrounding the treatment as prevention strategy

Currently, British Columbia is Canada's only province that adopts the "Treatment as Prevention" strategy to combat HIV/AIDS. [33] [34] Despite evidence from the B.C. Centre for Excellence indicating a reduction in transmission of HIV, increased survival and a reduction of viral load to an undetectable level, the "Treatment as Prevention" strategy has not been implemented as a federal policy by the Canadian government. [22] [33] [35] Under Montaner's leadership, the Center for Disease Control and Prevention in China and the B.C. Centre for Excellence in HIV/AIDS created a new Fellowship program in 2013 to help incorporate the "Treatment as Prevention Strategy" as China's national response to HIV/AIDS. [36] Brazil, Australia, the United States and France have also implemented "Treatment as Prevention" as a strategy for fighting HIV/AIDS. [33] [35] [37] The World Health Organization has also incorporated the strategy into its Global HIV Treatment Guidelines. [37]

The Government of Canada has not yet federally endorsed the program. The Public Health Agency of Canada (PHAC) released a statement saying more evaluation is needed to determine the feasibility, long-term sustainability, safety and effectiveness of new prevention technologies such as "Treatment as Prevention" in Canada and globally" and indicated that it is monitoring the results of pilot studies and randomized control trials. [35] The PHAC states that B.C.’s concurrent implementation of a comprehensive strategy to reduce HIV infections has made it difficult to isolate whether the "Treatment as Prevention" strategy is responsible for the decrease in HIV infections. [35]

Montaner stated his belief that the stigmas associates with the transmission routes of HIV are responsible for the Canadian government's hesitancy to embrace the strategy in an interview with the Globe and Mail in 2012. [35] He is outspoken about his opinion of the Government of Canada's current stance on funding HIV/AIDS and their focus on criminalizing injecting drug users. [35] [37] [38] He referred to his frustration with the federal government's hesitancy to adopt the Treatment as Prevention strategy in a 2012 interview with Positive Live, stating "Canada has this amazing made-in-Canada strategy that has now been recognized by Science as the number one scientific breakthrough for 2011. The New York Times has written about it. You name it. It’s all over the place. And I cannot get five minutes audience with the federal government to say – you know how come it‘s so easy to have a national strategy about childhood obesity, prostate cancer, breast cancer – and AIDS, we have a made-in-Canada strategy that can fix it that cannot be sorted out." [38]

Honours and recognition

Further reading

Articles on treatment as prevention

Articles on the discovery of the anti-HIV drug triple therapy

Related Research Articles

<span class="mw-page-title-main">Zidovudine</span> Antiretroviral medication

Zidovudine (ZDV), also known as azidothymidine (AZT), was the first antiretroviral medication used to prevent and treat HIV/AIDS. It is generally recommended for use in combination with other antiretrovirals. It may be used to prevent mother-to-child spread during birth or after a needlestick injury or other potential exposure. It is sold both by itself and together as lamivudine/zidovudine and abacavir/lamivudine/zidovudine. It can be used by mouth or by slow injection into a vein.

The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs as a strategy to control HIV infection. There are several classes of antiretroviral agents that act on different stages of the HIV life-cycle. The use of multiple drugs that act on different viral targets is known as highly active antiretroviral therapy (HAART). HAART decreases the patient's total burden of HIV, maintains function of the immune system, and prevents opportunistic infections that often lead to death. HAART also prevents the transmission of HIV between serodiscordant same-sex and opposite-sex partners so long as the HIV-positive partner maintains an undetectable viral load.

The spread of HIV/AIDS has affected millions of people worldwide; AIDS is considered a pandemic. The World Health Organization (WHO) estimated that in 2016 there were 36.7 million people worldwide living with HIV/AIDS, with 1.8 million new HIV infections per year and 1 million deaths due to AIDS. Misconceptions about HIV and AIDS arise from several different sources, from simple ignorance and misunderstandings about scientific knowledge regarding HIV infections and the cause of AIDS to misinformation propagated by individuals and groups with ideological stances that deny a causative relationship between HIV infection and the development of AIDS. Below is a list and explanations of some common misconceptions and their rebuttals.

<span class="mw-page-title-main">Nevirapine</span> Chemical compound

Nevirapine (NVP), sold under the brand name Viramune among others, is a medication used to treat and prevent HIV/AIDS, specifically HIV-1. It is generally recommended for use with other antiretroviral medications. It may be used to prevent mother to child spread during birth but is not recommended following other exposures. It is taken by mouth.

HIV/AIDS has been a public health concern for Latin America due to a remaining prevalence of the disease. In 2018 an estimated 2.2 million people had HIV in Latin America and the Caribbean, making the HIV prevalence rate approximately 0.4% in Latin America.

<span class="mw-page-title-main">HIV/AIDS</span> Spectrum of conditions caused by HIV infection

HIV is a retrovirus that attacks the immune system. It can be managed with treatment. Without treatment it can lead to a spectrum of conditions including AIDS.

<span class="mw-page-title-main">Raltegravir</span> Chemical compound

Raltegravir, sold under the brand name Isentress, is an antiretroviral medication used, together with other medication, to treat HIV/AIDS. It may also be used, as part of post exposure prophylaxis, to prevent HIV infection following potential exposure. It is taken by mouth.

<span class="mw-page-title-main">HIV/AIDS in Haiti</span>

With an estimated 150,000 people living with HIV/AIDS in 2016, Haiti has the most overall cases of HIV/AIDS in the Caribbean and its HIV prevalence rates among the highest percentage-wise in the region. There are many risk-factor groups for HIV infection in Haiti, with the most common ones including lower socioeconomic status, lower educational levels, risky behavior, and lower levels of awareness regarding HIV and its transmission.

<span class="mw-page-title-main">HIV disease–related drug reaction</span>

HIV disease–related drug reaction is an adverse drug reaction caused by drugs used for the treatment of HIV/AIDS.

<span class="mw-page-title-main">HIV-affected community</span> Medical condition

The affected community is composed of people who are living with HIV and AIDS, plus individuals whose lives are directly influenced by HIV infection. This originally was defined as young to middle aged adults who associate with being gay or bisexual men, and or injection drug users. HIV-affected community is a community that is affected directly or indirectly affected by HIV. These communities are usually influenced by HIV and undertake risky behaviours that lead to a higher chance of HIV infection. To date HIV infection is still one of the leading cause of deaths around the world with an estimate of 36.8 million people diagnosed with HIV by the end of 2017, but there can particular communities that are more vulnerable to HIV infection, these communities include certain races, gender, minorities, and disadvantaged communities. One of the most common communities at risk is the gay community as it is commonly transmitted through unsafe sex. The main factor that contributes to HIV infection within the gay/bisexual community is that gay men do not use protection when performing anal sex or other sexual activities which can lead to a higher risk of HIV infections. Another community will be people diagnosed with mental health issues, such as depression is one of the most common related mental illnesses associated with HIV infection. HIV testing is an essential role in reducing HIV infection within communities as it can lead to prevention and treatment of HIV infections but also helps with early diagnosis of HIV. Educating young people in a community with the knowledge of HIV prevention will be able to help decrease the prevalence within the community. As education is an important source for development in many areas. Research has shown that people more at risk for HIV are part of disenfranchised and inner city populations as drug use and sexually transmitted diseases(STDs) are more prevalent. People with mental illnesses that inhibit making decisions or overlook sexual tendencies are especially at risk for contracting HIV.

<span class="mw-page-title-main">Resistance Database Initiative</span> Not-for-profit organisation

HIV Resistance Response Database Initiative (RDI) was formed in 2002 to use artificial intelligence (AI) to predict how patients will respond to HIV drugs using data from more 250,000 patients from around 50 countries around the world.

HIV prevention refers to practices that aim to prevent the spread of the human immunodeficiency virus (HIV). HIV prevention practices may be undertaken by individuals to protect their own health and the health of those in their community, or may be instituted by governments and community-based organizations as public health policies.

For the American comedian and raconteur, see Myron Cohen.

HIV in pregnancy is the presence of an HIV/AIDS infection in a woman while she is pregnant. There is a risk of HIV transmission from mother to child in three primary situations: pregnancy, childbirth, and while breastfeeding. This topic is important because the risk of viral transmission can be significantly reduced with appropriate medical intervention, and without treatment HIV/AIDS can cause significant illness and death in both the mother and child. This is exemplified by data from The Centers for Disease Control (CDC): In the United States and Puerto Rico between the years of 2014–2017, where prenatal care is generally accessible, there were 10,257 infants in the United States and Puerto Rico who were exposed to a maternal HIV infection in utero who did not become infected and 244 exposed infants who did become infected.

Treatment as prevention (TasP) is a concept in public health that promotes treatment as a way to prevent and reduce the likelihood of HIV illness, death and transmission from an infected individual to others. Expanding access to earlier HIV diagnosis and treatment as a means to address the global epidemic by preventing illness, death and transmission was first proposed in 2000 by Garnett et al. The term is often used to talk about treating people that are currently living with human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) to prevent illness, death and transmission. Although some experts narrow this to only include preventing infections, treatment prevents illnesses such as tuberculosis and has been shown to prevent death. In relation to HIV, antiretroviral therapy (ART) is a three or more drug combination therapy that is used to decrease the viral load, or the measured amount of virus, in an infected individual. Such medications are used as a preventative for infected individuals to not only spread the HIV virus to their negative partners but also improve their current health to increase their lifespans. When taken correctly, ART is able to diminish the presence of the HIV virus in the bodily fluids of an infected person to a level of undetectability. Consistent adherence to an ARV regimen, monitoring, and testing are essential for continued confirmed viral suppression. Treatment as prevention rose to great prominence in 2011, as part of the HPTN 052 study, which shed light on the benefits of early treatment for HIV positive individuals.

Viral load monitoring for HIV is the regular measurement of the viral load of individual HIV-positive people as part of their personal plan for treatment of HIV/AIDS. A count of the viral load is routine before the start of HIV treatment.

<span class="mw-page-title-main">Bictegravir/emtricitabine/tenofovir alafenamide</span> Fixed dose combination HIV drug

Bictegravir/emtricitabine/tenofovir alafenamide, sold under the brand name Biktarvy, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. One tablet, taken orally once daily, contains 50 mg bictegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide.

The Swiss Statement, or the Swiss Consensus Statement, was an announcement published in January 2008 by the Swiss Federal Commission for AIDS/HIV outlining the conditions under which an HIV-positive individual could be considered functionally noncontagious—namely, adherence to antiretroviral therapy, a sufficiently low viral load, and a lack of any other sexually transmitted diseases. While lacking the backing of complete, fully randomized clinical studies, the Commission felt the contemporary evidence for non-contagiousness for people on antiretroviral treatment was nonetheless strong enough to warrant official publication.

<span class="mw-page-title-main">Charles Flexner</span> American physician and pharmaceutical scientist

Charles Williams Flexner is an American physician, clinical pharmaceutical scientist, academic, author and researcher. He is a Professor of Medicine at the Johns Hopkins University School of Medicine.

Robert S. Hogg is an HIV researcher focused on improving outcomes for people living with HIV/AIDS through the understanding of barriers to accessing HIV testing, treatment and care in Canada and globally. He is a senior research scientist and the former Director of the HIV/AIDS Drug Treatment Program at the B.C. Centre for Excellence in HIV/AIDS. He is a Simon Fraser University Distinguished Professor and the Associate Dean of Research of the faculty of Health Sciences. He is a prolific and highly cited author with an H-index of 111 and over 1000 peer-reviewed papers. He is both a Member of the Order of Canada and a Fellow of the Canadian Academy of Health Sciences.

References

[4] [51]

  1. ↑ "Dr. Julio S.G. Montaner, OC | Canadian Medical Hall of Fame". cdnmedhall.org. Canadian Medical Hall of Fame. Retrieved March 6, 2019.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 "RDI - Julio Montaner".
  3. 1 2 3 4 "F.N.G. Starr Award".
  4. 1 2 3 4 "The Passionate Physician". Vancouver Sun. August 15, 2006.
  5. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Pirisi, A. (25 November 2006). "Julio Montaner: King of HAART". Lancet. 368 (9550): 1863. doi:10.1016/S0140-6736(06)69762-6. PMID   17126706. S2CID   28667782.
  6. 1 2 3 4 5 6 7 8 Ryan, Denise (December 6, 2013). "AIDS: So Close to a Cure". Vancouver Sun.
  7. 1 2 3 4 "AIDS Free World: Julio Montaner".
  8. 1 2 The National Institutes of Health—University of California Expert Panel (1990). "Consensus Statement on the Use of Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia in the Acquired Immunodeficiency Syndrome". New England Journal of Medicine. 323 (21): 1500–1504. doi: 10.1056/NEJM199011223232131 . PMID   2136587.
  9. 1 2 3 Montaner, J.G.; Russel, J.; Lawson, L.; Ruedy, J. (1989). "Acute Respiratory Failure Secondary to Pneumocystis Carinii Pneumonia in the Acquired Immunodeficiency Syndrome: A Potential Role for Systemic Corticosteroids". Chest. 95 (4): 881–884. doi:10.1378/chest.95.4.881. PMID   2784373.
  10. 1 2 3 Montaner, J.G.; Russell, J.; Lawson, L.; Ruedy, J. (1990). "Corticosteroids Prevent Early Deterioration in Patients with Moderately Severe Pneumocystis carinii Pneumonia and the Acquired Immunodeficiency Syndrome (AIDS)". Annals of Internal Medicine. 113 (1): 14–20. doi:10.7326/0003-4819-113-1-14. PMID   2190515.
  11. 1 2 3 4 5 Berger, P.B. (1996). "Hope and Caution: Report from the XI International Conference on AIDS". CMAJ. 155 (6): 717–721. PMC   1335225 . PMID   8823218.
  12. 1 2 Montaner, Julio SG; Hogg, Robert S; O'Shaughnessy, Michael V (April 1997). "Emerging international consensus for use of antiretroviral therapy". The Lancet. 349 (9058): 1042. doi:10.1016/S0140-6736(05)62289-1. PMID   9107240. S2CID   12378921.
  13. 1 2 3 4 Montaner, J.G.; Reiss, P.; Cooper, D. (1998). "A Randomized, Double-Blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected Patients: The INCAS Trial". JAMA. 279 (12): 930–937. doi: 10.1001/jama.279.12.930 . PMID   9544767.
  14. 1 2 Harrigan, P. Richard; Hogg, Robert S.; Dong, Winnie W. Y.; Yip, Benita; Wynhoven, Brian; Woodward, Justin; Brumme, Chanson J.; Brumme, Zabrina L.; Mo, Theresa; Alexander, Chris S.; Montaner, Julio S. G. (February 2005). "Predictors of HIV Drug‐Resistance Mutations in a Large Antiretroviral‐Naive Cohort Initiating Triple Antiretroviral Therapy". The Journal of Infectious Diseases. 191 (3): 339–347. doi: 10.1086/427192 . PMID   15633092.
  15. ↑ Hogg, Robert S.; Bangsberg, David R.; Lima, Viviane D.; Alexander, Chris; Bonner, Simon; Yip, Benita; Wood, Evan; Dong, Winnie W. Y.; Montaner, Julio S. G.; Harrigan, P. Richard (2006). "Emergence of Drug Resistance Is Associated with an Increased Risk of Death among Patients First Starting HAART". PLOS Medicine. 3 (9): e356. doi: 10.1371/journal.pmed.0030356 . PMC   1569883 . PMID   16984218.
  16. ↑ "CfE: Treatment as Prevention". 2012-01-25.
  17. 1 2 3 4 5 6 7 8 9 Montaner, JS; Hogg, R; Wood, E; Kerr, T; Tyndall, M; Levy, AR; Harrigan, PR (Aug 5, 2006). "The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic". Lancet. 368 (9534): 531–6. doi:10.1016/S0140-6736(06)69162-9. PMID   16890841. S2CID   11466139.
  18. ↑ Fang, CT; Hsu, HM; Twu, SJ; Chen, MY; Chang, YY; Hwang, JS; Wang, JD; Chuang, CY; Division of AIDS and STD, Center for Disease Control, Department of Health, Executive, Yuan (Sep 1, 2004). "Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan". The Journal of Infectious Diseases. 190 (5): 879–85. doi: 10.1086/422601 . PMID   15295691.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  19. ↑ Levy, A.R.; James, D; Johnston, KM; Hogg, RS; Harrigan, PR; Harrigan, BP; Sobolev, B; Montaner, JS (Mar 2006). "The direct costs of HIV/AIDS care". The Lancet Infectious Diseases. 6 (3): 171–7. doi:10.1016/s1473-3099(06)70413-3. PMID   16500598.
  20. ↑ Kuritzkes, Daniel; Lange, Joep; Zewdie, Debrework (November 2003). "World Bank meeting concludes drug resistance should not prevent distribution of antiretroviral therapy to poor countries". Nature Medicine. 9 (11): 1343–1344. doi:10.1038/nm1103-1343b. PMID   14595419. S2CID   11300821.
  21. ↑ Montaner, Julio SG (July 2011). "Treatment as prevention—a double hat-trick". The Lancet. 378 (9787): 208–209. doi:10.1016/S0140-6736(11)60821-0. PMID   21763923. S2CID   44428932.
  22. 1 2 3 Cohen, Myron S.; Chen, Ying Q.; McCauley, Marybeth; Gamble, Theresa; Hosseinipour, Mina C.; Kumarasamy, Nagalingeswaran; Hakim, James G.; Kumwenda, Johnstone; Grinsztejn, Beatriz; Pilotto, Jose H.S.; Godbole, Sheela V.; Mehendale, Sanjay; Chariyalertsak, Suwat; Santos, Breno R.; Mayer, Kenneth H.; Hoffman, Irving F.; Eshleman, Susan H.; Piwowar-Manning, Estelle; Wang, Lei; Makhema, Joseph; Mills, Lisa A.; de Bruyn, Guy; Sanne, Ian; Eron, Joseph; Gallant, Joel; Havlir, Diane; Swindells, Susan; Ribaudo, Heather; Elharrar, Vanessa; Burns, David; Taha, Taha E.; Nielsen-Saines, Karin; Celentano, David; Essex, Max; Fleming, Thomas R. (11 August 2011). "Prevention of HIV-1 Infection with Early Antiretroviral Therapy". New England Journal of Medicine. 365 (6): 493–505. doi:10.1056/NEJMoa1105243. PMC   3200068 . PMID   21767103.
  23. 1 2 3 4 Montaner, Julio SG; Lima, Viviane D; Barrios, Rolando; Yip, Benita; Wood, Evan; Kerr, Thomas; Shannon, Kate; Harrigan, P Richard; Hogg, Robert S; Daly, Patricia; Kendall, Perry (August 2010). "Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study". The Lancet. 376 (9740): 532–539. doi:10.1016/S0140-6736(10)60936-1. PMC   2996043 . PMID   20638713.
  24. 1 2 3 "STOP HIV/AIDS" . Retrieved December 11, 2013.
  25. 1 2 Reddon, Hudson; Wood, Evan; Tyndall, Mark; Lai, Calvin; Hogg, Robert; Montaner, Julio; Kerr, Thomas (October 2011). "Use of North America's First Medically Supervised Safer Injecting Facility Among HIV-Positive Injection Drug Users". AIDS Education and Prevention. 23 (5): 412–422. doi:10.1521/aeap.2011.23.5.412. PMC   3799861 . PMID   22010805.
  26. 1 2 Wood, E.; Kerr, T; Tyndall, M.W.; Montaner, J.S. (Jun 2008). "The Canadian government's treatment of scientific process and evidence: inside the evaluation of North America's first supervised injecting facility". The International Journal on Drug Policy. 19 (3): 220–5. doi:10.1016/j.drugpo.2007.11.001. PMID   18551754.
  27. 1 2 Wood, E.; Tyndall, M. W.; Montaner, J. S.; Kerr, T. (21 November 2006). "Summary of findings from the evaluation of a pilot medically supervised safer injecting facility". Canadian Medical Association Journal. 175 (11): 1399–1404. doi:10.1503/cmaj.060863. PMC   1635777 . PMID   17116909.
  28. ↑ "Supreme Court of Canada: Canada (Attorney General) v. PHS Community". September 30, 2011. Retrieved December 11, 2013.
  29. 1 2 3 4 5 Hansen, Darah (November 8, 2009). "The Fight of His Life". The Vancouver Sun. Retrieved December 12, 2013.
  30. ↑ "Tiko Kerr" . Retrieved December 12, 2013.
  31. 1 2 Chan, Cheryl (October 20, 2012). "Tiko Kerr: Experimental drugs saved this 'old dog'". The Province. Archived from the original on March 30, 2014. Retrieved December 12, 2013.
  32. ↑ "Tiko Kerr gives painting to doctor who saved his life". The Straight. November 8, 2009. Retrieved December 9, 2013.
  33. 1 2 3 "Treatment as Prevention".
  34. ↑ Mehler Paperny, Anna (Sep 30, 2015). "Made-in-Canada HIV/AIDS treatment embraced by everyone but Canada". Global News.
  35. 1 2 3 4 5 6 Woo, Andrea (October 17, 2013). "B.C. the lone province to adopt HIV 'treatment as prevention' strategy". The Globe and Mail.
  36. ↑ "China Implements BC-CfE's Treatment as Prevention Strategy as the Country's National HIV/AIDS Policy".
  37. 1 2 3 Montaner, Julio (December 1, 2013). "Made-in-Canada HIV strategy embraced internationally — but not here". Toronto Star.
  38. 1 2 "Positive Lite: Interview with Julio Montaner".
  39. ↑ "CfE: Royal Society of Canada".
  40. ↑ "Order of B.C."
  41. ↑ "SFU Honorary Degrees 2010".
  42. ↑ "2010 Albert Einstein World of Science Award". 2010-11-03. Archived from the original on 2018-07-05. Retrieved 2013-12-15.
  43. ↑ "2010 Aubrey J. Tingle Prize". 2010-06-21.
  44. ↑ "2010 Prix Galien". 2010-06-21.
  45. ↑ "2011 UBC Jacob Biely Prize". 2010-06-21.
  46. ↑ "Grand Decoration of Honour". Archived from the original on 2014-01-13. Retrieved 2013-12-15.
  47. ↑ "QEII Diamond Jubilee Medal".
  48. ↑ "2013 HRF Medal of Honour". 2014-01-27.
  49. ↑ "Dr. Julio Montaner appointed Officer of the Order of Canada : Research pioneer recognized for helping establish global standard of care for HIV/AIDS". CBC News. 2014-12-26. Retrieved 2016-03-01.
  50. ↑ "THE CANADIAN MEDICAL HALL OF FAME ANNOUNCES 2015 INDUCTEES". cdnmedhall.org. Retrieved 7 October 2014.
  51. ↑ Pirisi, Angela (2006). "Julio Montaner: King of HAART". Lancet. 368 (9550): 1863. doi:10.1016/S0140-6736(06)69762-6. PMID   17126706. S2CID   28667782.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.